Last reviewed · How we verify

Treatment D — Competitive Intelligence Brief

Treatment D (treatment-d) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Single 875 mg dose of mevrometostat alternative tablet formulation. Area: Other.

discontinued Single 875 mg dose of mevrometostat alternative tablet formulation Other Live · refreshed every 30 min

Target snapshot

Treatment D (treatment-d) — Pfizer Inc.. Single 875 mg dose of mevrometostat alternative tablet formulation

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Treatment D TARGET treatment-d Pfizer Inc. discontinued Single 875 mg dose of mevrometostat alternative tablet formulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Single 875 mg dose of mevrometostat alternative tablet formulation class)

  1. Pfizer Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment D — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-d. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: